BlackRock’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-687,032
| Closed | -$454K | – | 5135 |
|
|
2017
Q4 | $454K | Buy |
687,032
+708
| +0.1% | +$357 | ﹤0.01% | 4068 |
|
|
2017
Q3 | $219K | Buy |
686,324
+1,197
| +0.2% | +$420 | ﹤0.01% | 4206 |
|
|
2017
Q2 | $315K | Sell |
685,127
-86,160
| -11% | -$62.6K | ﹤0.01% | 4137 |
|
|
2017
Q1 | $926K | Buy |
+771,287
| New | +$964K | ﹤0.01% | 3829 |
|
|
2015
Q2 | – | Sell |
-580
| Closed | -$5K | – | 3373 |
|
|
2015
Q1 | $5K | Hold |
580
| – | – | ﹤0.01% | 3063 |
|
|
2014
Q4 | $6K | Hold |
580
| – | – | ﹤0.01% | 3049 |
|
|
2014
Q3 | $6K | Hold |
580
| – | – | ﹤0.01% | 3059 |
|
|
2014
Q2 | $10K | Hold |
580
| – | – | ﹤0.01% | 2838 |
|
|
2014
Q1 | $10K | Hold |
580
| – | – | ﹤0.01% | 2769 |
|
|
2013
Q4 | $11K | Buy |
580
+84
| +17% | +$1.59K | ﹤0.01% | 2701 |
|
|
2013
Q3 | $13K | Hold |
496
| – | – | ﹤0.01% | 2525 |
|
|
2013
Q2 | $9K | Buy |
+496
| New | +$8.76K | ﹤0.01% | 2749 |
|
BlackRock's RPRX Position: Q1 2018 in Review
BlackRock sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 687,032 shares — an estimated $454K sold.
BlackRock first reported a position in RPRX in Q2 2013 and held it in 12 quarters. The position peaked at $926K in Q1 2017. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- BlackRock reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- BlackRock sold 687,032 Repros Therapeutics Inc. shares in Q1 2018, an estimated $454K.
- BlackRock first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 12 quarters.
- BlackRock's Repros Therapeutics Inc. position peaked at $926K in Q1 2017.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on BlackRock's 13F filing for Q1 2018, filed 9 May 2018.